© 2025 ISOMORPHIC LABS
.png)
At Isomorphic Labs, we’re harnessing AI’s extraordinary power to reimagine and advance the drug design process from first principles. The technology we have developed allows our researchers to explore a new chemical landscape, enabling them to take on historically challenging targets with increased pace and accuracy.
Our heritage of breakthroughs in this space is unique - we were launched from DeepMind and many of our team contributed to the creation of the groundbreaking AlphaFold system.
Now, the Isomorphic Labs team has built and developed even more advanced AI models that together form a unified state-of-the-art drug design engine that will transform how we design new drugs and ultimately change the way medicine will help and heal people.
.png)
Where others may build solutions around a specific design target, Iso’s drug design engine is built on AI models capable of working across multiple therapeutic areas and drug modalities.
Our pioneering AI-first approach means much of the time-consuming experimental work previously associated with identifying a drug candidate at the bench in a lab, can now be conducted much more quickly and efficiently ‘in silico’: on a computer.
This is unlocking exciting opportunities for Iso’s scientists to probe new chemical space, explore previously intractable targets with strong disease associations, and design new drug candidates with much greater pace and precision.
Iso’s breakthrough technology has helped to expand our drug discovery programs from small molecules to biologics and beyond. In addition to our partnered programs, we are also developing an internal drug candidate pipeline focused in oncology and immunology.
We developed and released AlphaFold 3 in May 2024. This latest generation model allows researchers to model the structures and interactions of all of life’s molecules with unprecedented accuracy. But to create a truly generalisable drug design engine, we have developed multiple further breakthroughs that tackle the full spectrum of complexity in drug design. This allows our AI drug design engine to operate end-to-end, in a way that is both target and disease agnostic.
Our models are developed, crafted and employed by our world-leading, interdisciplinary team of machine learning researchers and engineers, software developers, medicinal chemists, computational chemists and biologists, who are building on pioneering breakthroughs like AlphaFold.
Iso’s success relies on our brilliant teams working together, learning from and empowering each other every single day.
.svg)
